Biomed Central Ltd

SHERPA: Unknown

People

  1. Khalil
    Khalil
  2. Norton
    Norton
  3. Paty
    Paty
  4. Schultz
    Schultz
  5. Shoushtari
    Shoushtari
  6. Vickers
    Vickers
  7. Weiser
    Weiser
  8. Autio
    Autio
  9. Bao
    Bao
  10. Chaft
    Chaft

Groups

  1. Department of Medicine (23)
  2. GSK Faculty (17)
  3. Solid Tumor Oncology Division (17)
  4. Hematologic Malignancies, Division of (8)
  5. Sloan Kettering Institute Postdocs (8)
  6. Melanoma and Immunotherapeutics Service (7)
  7. Center for Hematologic Malignancies (6)
  8. Epidemiology and Biostatistics (6)
  9. Population Sciences Research Program (5)
  10. Sloan Kettering Institute Faculty (5)
Search Within
  1. "2015"
Formats
  1. Journal Article (33)
  2. Meeting Abstract (15)
  3. Conference Paper (1)
Groups
  1. Department of Medicine (23)
  2. GSK Faculty (17)
  3. Solid Tumor Oncology Division (17)
  4. Hematologic Malignancies, Division of (8)
  5. Sloan Kettering Institute Postdocs (8)
  6. Melanoma and Immunotherapeutics Service (7)

More Groups

People
  1. Jedd Wolchok (5)
  2. Alexander Shoushtari (2)
  3. Andrew Vickers (2)
  4. Craig Moskowitz (2)
  5. Danny Khalil (2)
  6. David Page (2)

More People

Years
  1. 2015 (49)
Publications
  1. Journal for ImmunoTherapy of Cancer (17)
  2. Genome Biology (5)
  3. BMC Cancer (4)
  4. BMC Bioinformatics (3)
  5. Breast Cancer Research (3)
  6. BMC Genomics (2)

More Publications

Results (49)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
    Meeting Abstract

    Bartell, H.; Wolchok, J.; Hodi, F. S.; Liu, H.; Wojtaszek, C.; Weber, J.
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save
  • Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
    Meeting Abstract

    Taylor, M.; Antonia, S.; Bendell, J.; Calvo, E.; Jäger, D.; de Braud, F.; Ott, P. A.; Pietanza, M. C.; Horn, L.; Le, D. T.; more...
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save
  • Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
    Meeting Abstract

    Khalil, D.; Merghoub, T.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save
  • CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - A phase I study
    Meeting Abstract

    Naing, A.; Infante, J. R.; Papadopoulos, K. P.; Autio, K. A.; Wong, D. J.; Falchook, G. S.; Patel, M. R.; Pant, S.; Whiteside, M.; Bendell, J.; more...
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save
  • Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
    Meeting Abstract

    Rizvi, N.; Chaft, J.; Balmanoukian, A.; Goldberg, S. B.; Sanborn, R. E.; Steele, K. E.; Rebelatto, M. C.; Gu, Y.; Karakunnel, J. J.; Antonia, S.
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save
  • An open-label, multicohort phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
    Meeting Abstract

    Ribrag, V.; Armand, P.; Kuruvilla, J.; Michot, J. M.; Moskowitz, C. H.; Marinello, P.; Snyder, E.; Balakumaran, A.; Shipp, M. A.; Zinzani, P. L.
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save
  • Optimizing engineered TCR T cell therapy for synovial sarcoma
    Meeting Abstract

    D’Angelo, S.; Merchant, M.; Melchiori, L.; Zhang, H.; Pandite, L.; Holdich, T.; Binder-Scholl, G.; Tap, W.; Fortin, M.; Peretz, Y.; more...
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save
  • An open label randomized phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)
    Meeting Abstract

    Hellmann, M.; Ramalingam, S.; Reck, M.; O'Byrne, K.; Paz-Ares, L.; Harbison, C. T.; Bhagavatheeswaran, P.; Nathan, F.; Brahmer, J.
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): Keynote-087
    Meeting Abstract

    Chen, R.; Armand, P.; Fanale, M. A.; Ribrag, V.; Zinzani, P. L.; Ricart, A. D.; Thompson, S.; Balakumaran, A.; Molin, D.; Shipp, M. A.; more...
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save
  • Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients
    Meeting Abstract

    Page, D. B.; Diab, A.; Yuan, J.; Dong, Z.; Soloman, S. B.; Patil, S.; Hudis, C. A.; Wolchok, J. D.; Norton, L.; McArthur, H. L.
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save